Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver

Clinical Cancer Research

Volumn 2, Issue 3, 1996, Pages 507-510

  Chazal, M ^b   Etienne, M C ^a   Renee N ^a   Bourgeon, A ^b   Richelme, H ^b   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b PASTEUR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG TOXICITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER; MALE; MIDDLE AGED; OXIDOREDUCTASES; PROSPECTIVE STUDIES;

EID: 0030005786     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Podschun, B., Wahler, G., and Schnackerz, K. D. Purification and characterization of dihydropyrimidine dehydrogenase from pig liver. Eur. J. Biochem., 185: 219-224, 1989.
2. Naguib, F. N M., El Kouni, M. H., and Cha, S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res., 45: 5402-5412, 1985.
3. Tuchman, M., Stoekeler, J. S., Klang, D. T., O'Dea, R., Ramnaraine, M. L., and Mirkin, B. L. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N. Engl. J. Med., 313: 245-249, 1985.
4. Diasio, R. B., Beavers, T. L., and Carpenter, J. T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil induced toxicity. J. Clin. Invest., 81: 47-51, 1988.
5. Harris, B. E., Carpenter, J. T., and Diasio, R. B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer (Phila.), 68: 499-501, 1991.
6. Houyau, P., Gay, C., Chatelut, E., Canal, P., Roché, H., and Milano, G. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J. Natl. Cancer Inst , 85: 1602-1603, 1993.
7. Fleming, R. A , Milano, G., Gaspard, M. H , Bargnoux, P. J., Thyss, A., Plagne, R., Renée, N., Schneider, M., and Demard, F. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur. J. Cancer, 29: 740-744, 1993.
8. Lu, Z., Zhang, R., and Diasio, R. B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients and clinical implication in 5-fluorouracil chemotherapy. Cancer Res., 53. 5433-5438, 1993.
9. Etienne, M. C., Lagrange, J. L., Dassonville, O., Fleming, R., Thyss, A., Renée, N., Schneider, M., Demard, F., and Milano, G. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol., 12: 2248-2253, 1994.
10. Harris, B. E., Song, R., Soong, S., and Diasio, R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protacted continuous infusion. Cancer Res., 50: 197-201, 1990.
11. Fleming, R. A., Milano, G., Thyss, A., Etienne, M. C., Renée, N., Schneider, M., and Demard, F. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res., 52: 2899-2902, 1992
12. Diasio, R. B., and Harris, B E Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 16: 215-237, 1989.
13. Milano, G., and Etienne, M. C. Potential importance of dihydropyrimidine dehydrogenase in cancer chemotherapy. Pharmacogenetics, 4: 301-306, 1994.
14. Diasio, R. B., and Lu, Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J. Clin. Oncol., 12: 2239-2242, 1994.
15. Santini, J , Milano, G., Thyss, A., Renée, N., Viens, P. Ayela, P., Schneider, M., and Demard, F. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br. J. Cancer, 59: 287-290, 1989.
16. Trump, D. L., Egorin, M J., Forrest, A , Willson, J. K., Remick, S., and Tutsch, K. Pharmacokinetic and pharmacodynamic analysis of 5-fluorouracil during 72 hour continuous infusion with and without dipyridamole. J. Clin. Oncol., 9: 2027-2037, 1991.
17. Milano, G., Etienne, M. C , Renée, N., Thyss, A., Schneider, M., Ramaioli, A., and Demard, F. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J. Clin. Oncol., 12: 1291-1295, 1994.
18. Albin, N., Johnson, M. R., Shahinian, H., Wang, K., and Diasio, R. B. Initial molecular characterization of human dihydropyrimidine dehydrogenase deficiency a pharmacogenetic syndrome predisposing to severe 5-fluorouracil toxicity. Proc. ASCO, 14: 420, 1995.
19. Stephan, F., Etienne, M. C., Wallays, C., Milano, G., and Clergue, F. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am. J. Med., in press, 1996.
20. Lu, Z. H., Zhang, R , and Diasio, R. B. Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties Biochem. Pharmacol., 46: 945-952, 1993.